Instil Bio (TIL) Stock Forecast, Price Target & Predictions
TIL Stock Forecast
Instil Bio stock forecast is as follows: an average price target of $78.25 (represents a 195.28% upside from TIL’s last price of $26.50) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.
TIL Price Target
The average price target for Instil Bio (TIL) is $78.25 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $180.00 to $2.00. This represents a potential 195.28% upside from TIL's last price of $26.50.
TIL Analyst Ratings
According to 4 Wall Street analysts, Instil Bio's rating consensus is 'Hold'. The analyst rating breakdown for TIL stock is 0 'Strong Buy' (0.00%), 1 'Buy' (25.00%), 3 'Hold' (75.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Instil Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Jack Allen | Robert W. Baird | $180.00 | $65.58 | 174.47% | 579.25% |
| Sep 16, 2024 | Mitchell Kapoor | H.C. Wainwright | $120.00 | $84.52 | 41.98% | 352.83% |
| Sep 12, 2024 | Mitchell Kapoor | H.C. Wainwright | $40.00 | $39.19 | 2.07% | 50.94% |
| Apr 12, 2024 | Kelly Shi | Jefferies | $11.00 | $11.06 | -0.54% | -58.49% |
| Dec 12, 2022 | - | Morgan Stanley | $2.00 | $0.84 | 138.32% | -92.45% |
| Jun 05, 2022 | Vikram Purohit | Morgan Stanley | $9.00 | $6.01 | 49.75% | -66.04% |
The latest Instil Bio stock forecast, released on Sep 16, 2024 by Jack Allen from Robert W. Baird, set a price target of $180.00, which represents a 174.47% increase from the stock price at the time of the forecast ($65.58), and a 579.25% increase from TIL last price ($26.50).
Instil Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 4 |
| Avg Price Target | - | $113.33 | $87.75 |
| Last Closing Price | $26.50 | $26.50 | $26.50 |
| Upside/Downside | -100.00% | 327.66% | 231.13% |
In the current month, the average price target of Instil Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Instil Bio's last price of $26.50. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 04, 2024 | JMP Securities | - | Market Perform | Initialise |
| Sep 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 23, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 12, 2024 | Jefferies | - | Hold | Downgrade |
| Dec 12, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Instil Bio's last stock rating was published by JMP Securities on Nov 04, 2024. The company Initialise its TIL rating from "null" to "Market Perform".
Instil Bio Financial Forecast
Instil Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | $1.90M | $1.90M | $1.90M | $1.90M | $1.90M | $1.90M | - | $1.00M |
| High Forecast | $1.90M | $1.90M | $1.90M | $1.90M | $1.90M | $1.90M | - | $1.00M |
| Low Forecast | $1.90M | $1.90M | $1.90M | $1.90M | $1.90M | $1.90M | - | $1.00M |
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | - | 1 |
| Surprise % | - | - | - | - | - | - | - | - |
Instil Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. TIL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Instil Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | - | 1 |
| EBITDA | - | - | - | - | - | - | - | $-30.54M |
| Avg Forecast | $1.14M | $1.14M | $1.14M | $1.14M | $1.14M | $1.14M | - | $600.00K |
| High Forecast | $1.14M | $1.14M | $1.14M | $1.14M | $1.14M | $1.14M | - | $600.00K |
| Low Forecast | $1.14M | $1.14M | $1.14M | $1.14M | $1.14M | $1.14M | - | $600.00K |
| Surprise % | - | - | - | - | - | - | - | -50.90% |
undefined analysts predict TIL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Instil Bio's previous annual EBITDA (undefined) of $NaN.
Instil Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | - | 1 |
| Net Income | - | - | - | - | - | - | - | $-53.84M |
| Avg Forecast | $-26.74M | $-25.64M | $-24.75M | $-21.95M | $-16.15M | $-13.71M | $-19.38M | $-53.79M |
| High Forecast | $-26.74M | $-25.64M | $-24.75M | $-21.95M | $-7.08M | $-13.71M | $-19.38M | $-53.79M |
| Low Forecast | $-26.74M | $-25.64M | $-24.75M | $-21.95M | $-25.14M | $-13.71M | $-19.38M | $-53.79M |
| Surprise % | - | - | - | - | - | - | - | 1.00% |
Instil Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TIL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Instil Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | - | 1 |
| SG&A | - | - | - | - | - | - | - | $12.91M |
| Avg Forecast | $41.13M | $41.13M | $41.13M | $41.13M | $41.13M | $41.13M | - | $21.64M |
| High Forecast | $41.13M | $41.13M | $41.13M | $41.13M | $41.13M | $41.13M | - | $21.64M |
| Low Forecast | $41.13M | $41.13M | $41.13M | $41.13M | $41.13M | $41.13M | - | $21.64M |
| Surprise % | - | - | - | - | - | - | - | 0.60% |
Instil Bio's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to TIL last annual SG&A of $12.91M (Dec 22).
Instil Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | - | 1 |
| EPS | - | - | - | - | - | - | - | $-0.41 |
| Avg Forecast | $-4.11 | $-3.94 | $-3.80 | $-3.37 | $-2.48 | $-2.11 | $-2.98 | $-8.27 |
| High Forecast | $-4.11 | $-3.94 | $-3.80 | $-3.37 | $-1.09 | $-2.11 | $-2.98 | $-8.27 |
| Low Forecast | $-4.11 | $-3.94 | $-3.80 | $-3.37 | $-3.86 | $-2.11 | $-2.98 | $-8.27 |
| Surprise % | - | - | - | - | - | - | - | 0.05% |
According to undefined Wall Street analysts, Instil Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TIL previous annual EPS of $NaN (undefined).
Instil Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.18 | $10.00 | 747.46% | Buy |
| CTMX | CytomX Therapeutics | $0.91 | $5.73 | 529.67% | Buy |
| TIL | Instil Bio | $26.50 | $78.25 | 195.28% | Hold |
| NUVB | Nuvation Bio | $2.63 | $6.75 | 156.65% | Buy |
| NXTC | NextCure | $1.31 | $3.00 | 129.01% | Buy |
| ASMB | Assembly Biosciences | $16.14 | $35.50 | 119.95% | Buy |
| ACHL | Achilles Therapeutics | $1.05 | $2.00 | 90.48% | Buy |